-
-
-
-
-
-
-
Syndax Pharmaceuticals (SNDX) PT Lowered to $33 at UBS as Revuforj New Starts Decline
-
-
-
-
-
-
-
Syndax publishes SAVE trial data on Revuforj combination therapy in AML
-
-
-
-
-
-
-
Syndax Pharmaceuticals (SNDX) PT Raised to $46 at Stifel
-
-
-
-
-
-
-
Syndax Pharmaceuticals (SNDX) spreader of April 22 puts, April 25 calls and April 28 calls
-
-
-
-
-
-
-
Syndax presents real-world data for menin inhibitor at ASH conference
-
-
-
-
-
-
-
Syndax Pharmaceuticals (SNDX) halted, news pending
-
-
-
-
-
-
-
Syndax Pharmaceuticals (SNDX) PT Raised to $51 at Citi, Opens 90d Catalyst Watch
-
479,047 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


